Novartis AG NVS
159.26 USD -2.26 (-1.40%)
At closeNov 3, 2026, 4:01 PM EST
159.26 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
158.93 Day range 161.77
123.24 52-week range 170.46
- YTD
- +15.51%
- 1 year
- +28.58%
Analyst view
Consensus: hold
Hold
Price target (mean) 154.80 -2.8% downside
Now 159.26
- Target (low)
- 130.00
- Target (mean)
- 154.80
- Target (high)
- 185.00
Ratings (0m) 11 5 buy · 4 hold · 2 sell
- Strong buy3
- Buy2
- Hold4
- Sell1
- Strong sell1
Recommendation trend
- This month 11
- 1 month ago 12
- 2 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.23 | 2.19 – 2.31 | 2.03 | +9.9% | 14.85B | +7.1% | 3 |
| Next quarter | 2.27 | 2.21 – 2.33 | 1.99 | +14.1% | 14.31B | +5.8% | 2 |
| Current year | 9.16 | 9.01 – 9.38 | 8.98 | +2.0% | 57.38B | +1.3% | 5 |
| Next year | 9.94 | 9.30 – 10.79 | 9.16 | +8.5% | 61.50B | +7.2% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Deutsche Bank | Downgrade | Hold | Sell |
| Sep 10, 2026 | HSBC | Upgrade | Reduce | Hold |
| Mar 26, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jan 6, 2026 | Barclays | Upgrade | Underweight | Equal-Weight |
| Dec 8, 2025 | JP Morgan | Upgrade | Neutral | Overweight |
| Sep 12, 2025 | Goldman Sachs | Downgrade | Neutral | Sell |
| Feb 13, 2025 | UBS | Downgrade | Buy | Neutral |
| Nov 19, 2024 | Erste Group | Downgrade | Buy | Hold |
| Oct 30, 2024 | BMO Capital | Maintained | Market Perform | Market Perform |
| Sep 11, 2024 | B of A Securities | Downgrade | Buy | Neutral |
| Sep 5, 2024 | Goldman Sachs | Downgrade | Buy | Neutral |
| Sep 3, 2024 | Jefferies | Downgrade | Buy | Hold |
| Jul 2, 2024 | Jefferies | Maintained | Buy | Buy |
| Apr 24, 2024 | BMO Capital | Maintained | Market Perform | Market Perform |
| Feb 23, 2024 | BMO Capital | Initiated | — | Market Perform |
| Jan 23, 2024 | Morgan Stanley | Initiated | — | Equal-Weight |
| Sep 25, 2023 | Morgan Stanley | Upgrade | Underweight | Equal-Weight |
| May 9, 2022 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Dec 6, 2021 | Exane BNP Paribas | Downgrade | Outperform | Neutral |
| Dec 3, 2021 | Bryan Garnier | Downgrade | Buy | Neutral |
| Sep 20, 2021 | Deutsche Bank | Downgrade | Hold | Sell |
| Mar 10, 2021 | Argus Research | Downgrade | Buy | Hold |
| Feb 1, 2021 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Jan 15, 2021 | Deutsche Bank | Initiated | — | Buy |
| Sep 1, 2020 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Feb 25, 2020 | Guggenheim | Downgrade | Buy | Neutral |
| Apr 25, 2019 | Guggenheim | Upgrade | Neutral | Buy |
| Apr 10, 2019 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| Nov 26, 2018 | Cowen & Co. | Upgrade | Market Perform | Outperform |
| Nov 19, 2018 | Goldman Sachs | Upgrade | Neutral | Conviction Buy |
